LMMY 10-K & 10-Q changes, risk factors and insider trading

We are a development-stage corporation with limited operations and limited revenues from our business operations. Our independent auditor has issued a going-concern opinion. This means that our independent auditor believes there is substantial doubt that we can continue as an on-going business for the next twelve months. We do not anticipate that we will generate significant revenues, until we have obtained sufficient funds to initiate a marketing program, of which there is no assurance.

Recent Change in Control

Effective December 6, 2024, there occurred a change in control of the Company On such date, pursuant to two separate stock purchase agreements (the Change-in-Control Agreements), Zhang Shengwu acquired a total of 5,250,000 shares of the Company’s common stock (the Acquired Shares), 5,000,000 of the Acquired Shares from Dwight Witmer and 250,000 of the Acquired Shares from Stephen Townsend. The Acquired Shares represent approximately 67.51% of the outstanding shares of the Company’s common stock and constitute voting control of the Company.

The total consideration paid by Mr. Shengwu for the Acquired Shares was $335,910 in cash, $318,410 to Mr. Witmer and $17,500 to Mr. Townsend.

In conjunction with the Change-in-Control Agreements, on December 6, 2024, Dwight Witmer resigned as a Director, CEO, CFO and Secretary of the Company, Stephen Townsend resigned as a Director and COO of the Company and Zhang Shengwu was appointed as the Sole Director, President, Chief Executive Officer and Secretary of the Company.

No change in the Company’s business plan occurred, as a result of this change in control.

Fiscal Year Ended May 31, 2025, Compared to Fiscal Year Ended May 31, 2024. During the fiscal year ended May 31, 2025, we generated $3,750 in revenues; during the fiscal year ended May 31, 2024, we generated $11,500 in revenues. Our net income for the fiscal year ended May 31, 2025, was $51,395 compared to a net loss of $25,807 for the fiscal year ended May 31, 2024.

Unless and until we obtain additional capital or our operations begin to generate significant revenues, of which there is no assurance, we expect that our operating expenses will remain at current levels.

At May 31, 2025. As of May 31, 2025, we had cash of $-0- and no working capital, compared to cash of $1,028 and a working capital deficit of $1,205 as of May 31, 2024.

Cash Flows

Cash Flows from Operating Activities. We have not generated positive cash flows from operating activities. For the fiscal year ended May 31, 2025, net cash flows used in operating activities was $4,528. For the fiscal year ended May 31, 2024, net cash flows used in operating activities was $12,484.

Cash Flows from Financing Activities. We have financed our operations primarily either from advances from our former sole executive officer or from third parties. For the fiscal year ended May 31, 2025, net cash provided by financing activities was $3,500. For the fiscal year ended May 31, 2024, net cash from financing activities was $5,657.

We currently have no off-balance sheet arrangements.

Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. Our report from our independent registered public accounting firm for the fiscal year ended January 31, 2025, includes an explanatory paragraph stating our company has recurring losses and limited operations which raise substantial doubt about its ability to continue as a going concern. If our company is unable to obtain adequate capital, we may be required to reduce the scope, delay, or eliminate some or all of its planned operations. These factors, among others, raise substantial doubt about our company’s ability to continue as a going concern.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

Use of Estimates. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Recent Accounting Pronouncements

Recent accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), (including its EITF, the AICPA and the SEC), did not or are not believed by management to have a material effect on our company’s present or future financial statements.

Going Concern

Cautionary Note Regarding Forward-Looking Statements

This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, without limitation, statements concerning our plans, objectives, expectations, intentions, beliefs and assumptions about future events. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks and uncertainties that could cause our actual results to differ materially from those expressed or implied by such forward-looking statements, including our ability to continue as a going concern, our ability to execute on the business plan adopted in connection with our acquisition of Exousia AI, Inc., our ability to obtain additional financing on acceptable terms, our limited operating history under our current line of business, and other risks described in our filings with the Securities and Exchange Commission. We assume no obligation to update any forward-looking statement, except as required by law. The following discussion should be read in conjunction with the unaudited financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q.

Overview

Exousia AI is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. Substantially all of the Company’s prospective operations relate to the business of Exousia AI. We are a development-stage company with limited operating history under our current business plan and have not yet generated revenue from that business plan.

Recent Developments

The following developments are material to a comparison of our historical financial condition and results of operations to expected future periods:

• Amended and Restated Articles; Name Change. On January 16, 2026, the Company filed an Articles of Amendment to its Articles of Incorporation in the form of Amended and Restated Articles of Incorporation, which (i) changed the Company’s name to “Exousia Bio, Inc.,” (ii) increased its authorized common stock to 100,000,000 shares ($0.0001 par value) and authorized 1,000,000 shares of preferred stock ($0.0001 par value), and (iii) designated one (1) share of Series X Preferred Stock with voting power equal to two (2) times the sum of all outstanding common stock and any other voting preferred stock.

• Series X Preferred Issuance. In January 2026, the Company issued the one outstanding share of Series X Preferred Stock to Exousia Pro Holding Management, LLC, the Company’s majority common stockholder, for the stated purpose of assuring stability and continuity of strategic control during the Company’s initial stages of development under its new business plan.

• Convertible Promissory Note. On January 20, 2026 (funded January 26, 2026), the Company issued a $250,000 convertible promissory note (the “Convertible Note”) to GBII Partners Inc. The Convertible Note bears interest at 15% per annum (18% on default) and matured on March 26, 2026. Conversion price is 50% of market price on or before maturity, with further discounts (35%, 20% and 10% of market price) at successive 30-day intervals after maturity. The Note is secured by 5,000,000 pledged shares from the Company’s majority stockholder and 1,276,225 pledged shares from VS Services, LLC. The Company created a reserve of 3,333,334 shares of common stock at its transfer agent in favor of the noteholder.

• Rescission Agreement. Effective March 14, 2026, the Company entered into a Rescission Agreement and Mutual Release with Progenicyte Japan CO., LTD., under which the 21,000,000 shares of Company common stock previously issued to Progenicyte under the Reorganization Agreement were cancelled, based on a mutual mistake of fact, with the parties releasing each other from all claims. As of February 28, 2026, this cancellation had not yet occurred and the 21,000,000 Progenicyte shares are reflected in the issued-and-outstanding common stock count at that date.

• Service Agreement with ProgeniX. Effective May 1, 2026, the Company entered into a Service Agreement with ProgeniX under which ProgeniX will provide technical support and operational assistance, exosome production guidance, laboratory and equipment planning, protocol development, and quality control and analytical support to the Company. The Company will pay ProgeniX a monthly fee of $10,000, subject to upward adjustment in defined circumstances.

Our unaudited financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. As of February 28, 2026, we had no cash, an accumulated deficit of $288,623, total current liabilities of $261,023 and a working-capital deficit of $261,023. We have not yet established an ongoing source of revenue sufficient to cover our operating costs, and our continuation as a going concern is dependent upon, among other things, our ability to raise additional capital from management, significant shareholders and third-party investors and to execute on the business plan adopted in connection with our acquisition of Exousia AI. There can be no assurance that we will be successful in these efforts. These conditions raise substantial doubt about our ability to continue as a going concern for a reasonable period of time. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. See Note 2 to our unaudited financial statements.

Three Months Ended February 28, 2026 Compared to Three Months Ended February 28, 2025

Revenue. We generated no revenue during the three months ended February 28, 2026 or during the three months ended February 28, 2025. We do not expect to generate revenue from the Exousia AI line of business until our research and development activities have advanced sufficiently to permit commercialization of one or more product candidates, of which there is no assurance.

Cost of Goods Sold; Gross Loss. We recorded cost of goods sold of $62,108 during the three months ended February 28, 2026, resulting in a gross loss of $62,108, compared to no cost of goods sold and no gross loss for the three months ended February 28, 2025. The cost of goods sold incurred during the 2026 quarter related to initial product-development costs incurred under our new business plan.

Operating Expenses. Total operating expenses for the three months ended February 28, 2026 were $174,897, consisting of office supplies of $1,317, delivery of $64, transfer-agent fees of $1,490, professional fees of $10,600 and research and development of $161,426. For the three months ended February 28, 2025, total operating expenses were $6,981, consisting solely of general and administrative expenses. The $167,916 increase is primarily attributable to research-and-development activities undertaken following the Acquisition and to higher professional fees incurred in connection with the Acquisition, the change in our business plan, the Amended and Restated Articles, and the GBII Convertible Note.

Other Income (Expense). Other income for the three months ended February 28, 2026 was $217,922, consisting of a gain on acquisition of $217,922. Other income for the three months ended February 28, 2025 was $87,110, consisting of other income unrelated to our current business plan.

Net Loss. We reported a net loss of $19,083 for the three months ended February 28, 2026, compared to net income of $80,129 for the three months ended February 28, 2025. Loss per share, basic and diluted, was less than $0.01 for the three months ended February 28, 2026, compared to income per share, basic and diluted, of $0.01 for the three months ended February 28, 2025. Weighted average shares outstanding were 16,764,767 for the 2026 quarter and 7,777,000 for the 2025 quarter, reflecting the Acquisition Shares issued in November 2025 and the consulting shares issued in February 2026.

Nine Months Ended February 28, 2026 Compared to Nine Months Ended February 28, 2025

Revenue. We generated no revenue during the nine months ended February 28, 2026, compared to $3,750 of revenue during the nine months ended February 28, 2025, all of which related to our pre-Acquisition financial-education business operations.

Cost of Goods Sold; Gross Loss. We recorded cost of goods sold of $62,108 during the nine months ended February 28, 2026, resulting in a gross loss of $62,108, compared to no cost of goods sold and gross profit of $3,750 for the nine months ended February 28, 2025.

Operating Expenses. Total operating expenses for the nine months ended February 28, 2026 were $206,711, consisting of advertising and promotion of $2,996, dues and subscriptions of $568, office supplies of $1,317, delivery of $64, transfer-agent fees of $1,490, OTC Markets fees of $7,500, professional fees of $31,350 and research and development of $161,426. For the nine months ended February 28, 2025, total operating expenses were $10,632, consisting solely of general and administrative expenses. The increase in operating expenses is primarily attributable to professional fees and research-and-development activities undertaken in connection with the Acquisition and the adoption of the new business plan.

Other Income (Expense). Other income for the nine months ended February 28, 2026 was $217,922, consisting of a gain on acquisition. Other income for the nine months ended February 28, 2025 was $87,541.

Net Loss. We reported a net loss of $50,897 for the nine months ended February 28, 2026, compared to net income of $80,659 for the nine months ended February 28, 2025. Loss per share, basic and diluted, was less than $0.01 for the 2026 nine-month period, compared to income per share, basic and diluted, of less than $0.01 for the 2025 nine-month period. Weighted average shares outstanding were 12,270,883 for the 2026 nine-month period and 7,000,000 for the 2025 nine-month period.

Cash and Working Capital Position

As of February 28, 2026, we had no cash and cash equivalents, total current assets of $0 and total current liabilities of $261,023, resulting in a working-capital deficit of $261,023. As of May 31, 2025, we had no cash, no current assets and no current liabilities. Our total assets at February 28, 2026 were $22,050,670, consisting of $670 of equipment and $22,050,000 of Other Assets representing the recorded value of our investment in Exousia AI. Our total liabilities at February 28, 2026 of $261,023 consisted of $8,831 of amounts due to a related party, $38,850 of advances from related parties, $212,302 of accounts payable and $1,040 of other current liabilities. Our total stockholders’ equity at February 28, 2026 was $21,789,647, compared to a deficiency of approximately $54,895 at May 31, 2025 (after giving effect to the Acquisition adjustment), reflecting the issuance of the Acquisition Shares and the consulting shares net of the related accumulated-deficit adjustments and net loss for the period.

Our current liquidity position is insufficient to satisfy our outstanding obligations as they come due. In particular, the $250,000 GBII Convertible Note matured on March 26, 2026, and the Company does not currently have the cash resources to satisfy that obligation. The Note is subject to material increases in the conversion-price discount upon default, as described above under “Recent Developments,” which may result in material dilution to our shareholders if the Note is converted rather than repaid.

Cash Flows

The following discussion is intended to provide investors with an understanding of the underlying reasons for changes in our cash flows between periods and to comply with the requirements of Item 303(a) of Regulation S-K and SEC Release No. 33-8350. The Acquisition closed on November 17, 2025 and was settled principally through the non-cash issuance of the 62,223,000 Acquisition Shares; accordingly, the cash flow effects discussed below are limited.

Cash Flows from Operating Activities. Net cash provided by operating activities was $176,626 for the nine months ended February 28, 2026, compared to net cash provided by operating activities of $86,538 for the nine months ended February 28, 2025. The increase reflects the deferral of substantially all operating expenses incurred in connection with the Acquisition, the change in business plan and post-Acquisition activities into accounts payable, advances from related parties and other accrued liabilities, rather than cash outflows.

Cash Flows from Investing Activities. Net cash used in investing activities for the nine months ended February 28, 2026 was $22,050,670, principally reflecting the recorded value of our investment in Exousia AI ($22,050,000) and the acquisition of equipment ($670). The Exousia AI investment was settled through the issuance of the Acquisition Shares and is a non-cash transaction; investors should refer to the supplemental disclosures of non-cash investing and financing activities to our Statements of Cash Flows for additional information. Net cash used in investing activities for the nine months ended February 28, 2025 was zero.

Cash Flows from Financing Activities. Net cash provided by financing activities for the nine months ended February 28, 2026 was $21,874,043, principally reflecting the value attributed to the Acquisition Shares ($22,050,000), partially offset by the recorded gain on acquisition ($175,957). The financing inflows attributable to the Acquisition Shares were non-cash and were offset by the non-cash investing outflow described above; accordingly, net change in cash for the nine months ended February 28, 2026 was zero. Net cash used in financing activities for the nine months ended February 28, 2025 was $86,538.

Material Cash Requirements

Over the next twelve months, our material cash requirements consist of (i) repayment or restructuring of the $250,000 GBII Convertible Note, which matured on March 26, 2026 and is past due as of the date of this Quarterly Report; (ii) recurring monthly service fees of $10,000 payable to ProgeniX under the May 1, 2026 Service Agreement, plus potential upward adjustments; (iii) research-and-development expenditures relating to the Company’s clinical-stage biotechnology business plan; (iv) ongoing SEC reporting, transfer-agent and OTC Markets fees; and (v) general and administrative expenses (legal, audit, accounting). We do not have, and do not currently expect to have, sufficient cash on hand to fund these obligations. We expect to fund them through some combination of conversion or restructuring of the GBII Convertible Note, additional equity or convertible-debt financings, and advances from related parties. There can be no assurance that any such financing will be available on acceptable terms, or at all. Additional issuances of equity or convertible-debt securities will result in dilution to existing shareholders, and the dilution caused by conversion of the GBII Convertible Note at the default conversion prices described above could be substantial.

We expect that working-capital requirements will continue to be funded through a combination of existing funds, further issuances of equity or convertible-debt securities and advances from related parties. Our working-capital requirements are expected to increase materially in line with the build-out of the Exousia AI business plan, including research-and-development expenditures, professional fees, regulatory compliance costs and personnel additions. We have no lines of credit or other bank financing arrangements in place. Generally, we have financed our operations to date through the private placement of equity and debt instruments. We currently do not have a definitive plan as to how we will obtain sufficient additional funding for the development and commercialization of the Exousia AI business plan, and there can be no assurance that we will be able to obtain such funding on terms that are acceptable to us, or at all.

As of February 28, 2026 and May 31, 2025, we did not have any off-balance sheet arrangements (as that term is defined in Item 303(a)(4) of Regulation S-K) that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, results of operations, liquidity, capital expenditures or capital resources.

Accounting for the Acquisition of Exousia AI

The Acquisition was completed in November 2025 and was accounted for as an asset acquisition. The value attributed to the Acquisition Shares issued as consideration ($22,050,000) was recorded as Other Assets at February 28, 2026 and is subject to evaluation for impairment in accordance with ASC 360. The fair value of the Exousia AI investment, and any associated impairment indicators, will be reassessed each reporting period based on management’s assessment of the recoverable amount of the underlying business and intellectual property of Exousia AI.

Convertible Note — Accounting for Conversion Features

We evaluate conversion options embedded in convertible instruments under ASC 815, Derivatives and Hedging Activities. We have evaluated the variable-discount conversion feature in the GBII Convertible Note and concluded that, under our current accounting policy, the conversion option does not require bifurcation as a freestanding derivative. The continuing application of this judgment is reassessed each reporting period; a change in conclusion could result in the recognition of a material derivative liability and corresponding non-cash income or expense in future periods.

Going-Concern Assessment